Screener
Amphastar Pharmaceuticals AMPH Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total non-operating expenses, net | (1,185) | (2,849) | (4,763) | (9,280) |
| Income before income taxes | 38,544 | 39,335 | 48,596 | 70,197 |
| Income tax provision | 8,196 | 8,305 | 11,828 | 13,882 |
| Net income | $30,348 | $31,030 | $36,768 | $56,315 |
| Net income per share: | ||||
| Basic | $0.69 | $0.66 | $0.83 | $1.19 |
| Diluted | $0.67 | $0.64 | $0.81 | $1.15 |
| Weighted-average shares used to compute net income per share: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's net income?
- Amphastar Pharmaceuticals (AMPH) reported net income of $30.35M in Q2 2026.
- How has Amphastar Pharmaceuticals's net income changed year-over-year?
- Amphastar Pharmaceuticals's net income decreased by 2.2% year-over-year, from $31.03M to $30.35M.
- What is the long-term trend for Amphastar Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's net income has grown at a 12.1% compound annual growth rate (CAGR), from $62.12M to $98.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Amphastar Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude